Greenwich LifeSciences (GLSI) Cash & Equivalents (2019 - 2025)

Greenwich LifeSciences' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $6.2 million for Q4 2025.

• Quarterly Cash & Equivalents rose 50.98% year-over-year to $6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.2 million (up 50.98% YoY) and the FY2025 annual result came in at $6.2 million, up 50.98% from the prior year.
• Cash & Equivalents was $6.2 million for Q4 2025 at Greenwich LifeSciences, up from $3.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $30.4 million in Q1 2021 and bottomed at $2.7 million in Q1 2025.
• A 5-year average of $13.0 million and a median of $10.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 365.15% — and 2025, when it sank 56.75%.
• Greenwich LifeSciences' Cash & Equivalents stood at $27.2 million in 2021, then sank by 50.49% to $13.5 million in 2022, then tumbled by 48.1% to $7.0 million in 2023, then slumped by 41.45% to $4.1 million in 2024, then soared by 50.98% to $6.2 million in 2025.
• Business Quant data shows GLSI's Cash & Equivalents at $6.2 million in Q4 2025, $3.8 million in Q3 2025, and $3.1 million in Q2 2025.